Mortality After Repeat Revascularization Following PCI or Coronary Artery Bypass Grafting for Left Main Disease: The EXCEL Trial.

[1]  P. Serruys,et al.  Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. , 2019, Journal of the American College of Cardiology.

[2]  P. Serruys,et al.  PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[3]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[4]  P. Serruys,et al.  Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention: An Individual Patient Data Pooled Analysis of 21 Randomized Trials and 32,524 Patients. , 2018, JACC. Cardiovascular interventions.

[5]  P. Serruys,et al.  Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial. , 2017, Journal of the American College of Cardiology.

[6]  C. Patrono,et al.  Mechanisms, Consequences, and Prevention of Coronary Graft Failure , 2017, Circulation.

[7]  P. Serruys,et al.  Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease , 2017 .

[8]  Deepak L. Bhatt,et al.  Short‐versus long‐term Dual Antiplatelet therapy after drug‐eluting stent implantation in women versus men: A sex‐specific patient‐level pooled‐analysis of six randomized trials , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  M. Mack,et al.  Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting: The SYNTAX Trial at 5 Years. , 2016, JACC. Cardiovascular interventions.

[10]  O. Alfieri,et al.  Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry. , 2016, JACC. Cardiovascular interventions.

[11]  S. Pocock,et al.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. , 2016, The New England journal of medicine.

[12]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. , 2016, Journal of the American College of Cardiology.

[13]  J. Alexander,et al.  Coronary-Artery Bypass Grafting. , 2016, The New England journal of medicine.

[14]  Deepak L. Bhatt,et al.  CORONARY Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery Insights From the Veterans Affairs Clinical Assessment , Reporting , and Tracking Program , 2022 .

[15]  P. Serruys,et al.  Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. , 2016, JACC. Cardiovascular interventions.

[16]  P. Serruys,et al.  Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis , 2016, Circulation. Cardiovascular interventions.

[17]  F. Crea,et al.  The Choice of Conduits in Coronary Artery Bypass Surgery. , 2015, Journal of the American College of Cardiology.

[18]  S. Windecker,et al.  Stable coronary artery disease: revascularisation and invasive strategies , 2015, The Lancet.

[19]  Giuseppe Biondi-Zoccai,et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.

[20]  Samin K. Sharma,et al.  Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.

[21]  D. Taggart.  Percutaneous or surgical revascularization in multivessel coronary artery disease: synthesis from SYNTAX. , 2014, European heart journal.

[22]  J. Spertus,et al.  Rethinking Composite End Points in Clinical Trials: Insights From Patients and Trialists , 2014, Circulation.

[23]  V. Fuster,et al.  Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. , 2013, JAMA.

[24]  Mark A Hlatky,et al.  Editorial Repeat Revascularization Is a Faulty End Point for Clinical Trials Article See P 267 the Syntax Trial , 2022 .

[25]  P. Serruys,et al.  Do Differences in Repeat Revascularization Explain the Antianginal Benefits of Bypass Surgery Versus Percutaneous Coronary Intervention?: Implications for Future Treatment Comparisons , 2012, Circulation. Cardiovascular quality and outcomes.

[26]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[27]  Sunil V. Rao,et al.  Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. , 2011, JACC. Cardiovascular interventions.

[28]  P. Serruys,et al.  Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. , 2011, The New England journal of medicine.

[29]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[30]  P. Teirstein.  Percutaneous Revascularization Is the Preferred Strategy for Patients With Significant Left Main Coronary Stenosis , 2009, Circulation.

[31]  Kevin E. Kip,et al.  The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.